

Press Briefing Schedule At-a-Glance

All on-site Press Briefings are located in McCormick Place, Lakeside Building E353a

Thursday, May 26	Friday, June 3	Saturday, June 4	Sunday, June 5	Monday, June 6
<p>Pre-Meeting Briefing</p> <p>Press Briefing Time: 12:00-1:30 PM (ET) <i>Virtual event conducted via live teleconference and webinar</i></p> <p>Embargo Lifts: 5:00 PM (ET)</p> <p>Abstract 6509: State public welfare spending and racial/ethnic disparities in overall survival among adults with cancer.</p> <p>Abstract 10005: Racial, ethnic, and socioeconomic survival disparities among children with high-risk neuroblastoma treated on upfront Children’s Oncology Group clinical trials.</p> <p>Abstract 1014: Increasing Black patient participation in metastatic breast cancer clinical trials: The BECOME (Black Experience of Clinical Trials and Opportunities for Meaningful Engagement) project.</p> <p>Abstract 6511: Racial and socioeconomic disparities in telemedicine use among US patients initiating cancer treatment during the COVID-19 pandemic.</p>	<p>News of the Day</p> <p>Press Briefing Time: 12:30-1:15 PM (CT)</p> <p>Embargo Lifts: 7:00 AM (CT)</p> <p>LBA7502: Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).</p> <p>LBA4011: Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.</p>	<p>News of the Day</p> <p>Press Briefing Time: 8:00-9:00 AM (CT)</p> <p>Embargo Lifts: 7:00 AM (CT)</p> <p>LBA100: Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC Trial.</p> <p>LBA1001: Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer.</p>	<p>News of the Day</p> <p>Press Briefing Time: 8:00-9:00 AM (CT)</p> <p>Embargo Lifts: 7:00 AM (CT)</p> <p>LBA1: Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.</p> <p>LBA2: Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).</p> <p>LBA3: Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.</p> <p>LBA4: Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.</p>	<p>News of the Day</p> <p>Press Briefing Time: 8:00-9:00 AM (CT)</p> <p>Embargo Lifts: 7:00 AM (CT) on June 6 and June 7*</p> <p>LBA2002: Primary analysis of a phase II trial of dabrafenib + trametinib (dab + tram) in BRAF V600–mutant pediatric low-grade glioma (pLGG).</p> <p>LBA501: LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).*</p> <p>*Based on scientific presentation, embargo on this abstract lifts at 7:00 AM (CT) on Tuesday, June 7</p>